Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

'Rapid Kill' Antibiotic Awaits US Data For Blanket Decolonization Prior To Surgery

This article was originally published in Scrip

Executive Summary

Destiny Pharma Ltd., a small UK antibiotic developer, and its lead "rapidly bactericidal" product XF-73, has placed itself firmly on the radar in the US. The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, is sponsoring and funding a clinical trial which is expected to complete in the coming weeks. If successful, XF-73 will be filed for the prevention of post-surgical Staphylococcal infections, a completely new indication. CEO Dr Bill Love explained to Scrip why the interest in Destiny's child.

Advertisement

Related Content

Quick Acting Antibiotic Lends Promise To Destiny's Future

Topics

Advertisement
UsernamePublicRestriction

Register

SC064657

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel